Active Ingredient(s): Caplacizumab-yhdp
FDA Approved: * February 6, 2019
Pharm Company: * ABLYNX NV
Category: Blood Clotting (Hemostasis)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Cablivi Overview

Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[2][3][4][5] This drug was developed by Ablynx NV.[6] On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchang...

Read more Cablivi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Cablivi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 11mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cablivi: (1 result)

Sorted by National Drug Code
  • 58468-0225 CabliviCablivi Intravenous; Subcutaneous Kit by Genzyme Corporation

Other drugs which contain Caplacizumab-yhdp or a similar ingredient: (1 result)